AstraZeneca CEO on Vaccine Unit, Covid Endemic Stage

AstraZeneca CEO on Vaccine Unit, Covid Endemic Stage

Assessment

Interactive Video

Business, Health Sciences, Biology

University

Hard

Created by

Quizizz Content

FREE Resource

The transcript covers AstraZeneca's sales guidance for 2022, driven by new products in oncology and COVID-19 protection. The company plans to build its COVID-19 division without selling or spinning it off, expecting a decline in vaccine demand but growth in antibodies. The pandemic is transitioning to an endemic phase, requiring ongoing protection for vulnerable groups. CEO Pascal Soriot remains committed to leading AstraZeneca, aiming for leadership in oncology by 2025. Regulatory challenges are discussed, emphasizing the need for diverse clinical trial data.

Read more

7 questions

Show all answers

1.

OPEN ENDED QUESTION

3 mins • 1 pt

What percentage growth is AstraZeneca forecasting for 2022?

Evaluate responses using AI:

OFF

2.

OPEN ENDED QUESTION

3 mins • 1 pt

How does AstraZeneca describe the new targets they have set?

Evaluate responses using AI:

OFF

3.

OPEN ENDED QUESTION

3 mins • 1 pt

What does Pascal say about the future of the new unit housing COVID-19 assets?

Evaluate responses using AI:

OFF

4.

OPEN ENDED QUESTION

3 mins • 1 pt

What is the expected trend for AstraZeneca's COVID-19 franchise according to the discussion?

Evaluate responses using AI:

OFF

5.

OPEN ENDED QUESTION

3 mins • 1 pt

How does Pascal view the current state of the pandemic?

Evaluate responses using AI:

OFF

6.

OPEN ENDED QUESTION

3 mins • 1 pt

What challenges does AstraZeneca face in the oncology sector?

Evaluate responses using AI:

OFF

7.

OPEN ENDED QUESTION

3 mins • 1 pt

What is AstraZeneca's approach to the diversity of clinical trials?

Evaluate responses using AI:

OFF